Balancing the risks: continuous vs. interrupted anticoagulation during TAVI – what does the evidence say?
Abstract Anticoagulation therapy is a critical component of post-transcatheter aortic valve implantation (TAVI) management, aimed at reducing the risk of thromboembolic events and mortality. This review examines the efficacy of continuous versus interrupted anticoagulation strategies in TAVI patient...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Thrombosis Journal |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12959-025-00686-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585437683646464 |
|---|---|
| author | Ravi Patel Emmanuel Kokori Gbolahan Olatunji Israel Charles Abraham Adeola Akinboade Emmanuel Ababio Agyemang Adetola Babalola Nicholas Aderinto |
| author_facet | Ravi Patel Emmanuel Kokori Gbolahan Olatunji Israel Charles Abraham Adeola Akinboade Emmanuel Ababio Agyemang Adetola Babalola Nicholas Aderinto |
| author_sort | Ravi Patel |
| collection | DOAJ |
| description | Abstract Anticoagulation therapy is a critical component of post-transcatheter aortic valve implantation (TAVI) management, aimed at reducing the risk of thromboembolic events and mortality. This review examines the efficacy of continuous versus interrupted anticoagulation strategies in TAVI patients, focusing on mortality, stroke rates, and composite events. A literature review was conducted, analyzing recent studies that evaluate the impact of different anticoagulation regimens on clinical outcomes in TAVI patients. Key outcomes assessed include all-cause mortality, thromboembolic events, and major cardiovascular complications within 30 days and up to one year post-procedure. The review identifies a trend favoring continuous anticoagulation, particularly with direct-acting oral anticoagulants (DOACs), which was associated with lower mortality rates and reduced stroke incidence in high-risk patients. However, findings were inconsistent across studies, with some reporting no significant differences in outcomes between continuous and interrupted strategies. Additionally, the review highlights the need to balance the benefits of thromboembolic prevention with the increased risk of bleeding and vascular complications associated with continuous therapy. The findings show the importance of individualized anticoagulation strategies tailored to patient risk profiles. Clinicians should weigh the potential benefits of continuous anticoagulation against the risks, particularly in high-risk populations. Ongoing research is essential to refine anticoagulation protocols in TAVI patients, enhancing both safety and efficacy in clinical practice. |
| format | Article |
| id | doaj-art-8f3ba616f36a4cbc96d25f575a887825 |
| institution | Kabale University |
| issn | 1477-9560 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Thrombosis Journal |
| spelling | doaj-art-8f3ba616f36a4cbc96d25f575a8878252025-01-26T12:48:24ZengBMCThrombosis Journal1477-95602025-01-0123111310.1186/s12959-025-00686-zBalancing the risks: continuous vs. interrupted anticoagulation during TAVI – what does the evidence say?Ravi Patel0Emmanuel Kokori1Gbolahan Olatunji2Israel Charles Abraham3Adeola Akinboade4Emmanuel Ababio Agyemang5Adetola Babalola6Nicholas Aderinto7Methodist Health System DallasDepartment of Medicine and Surgery, University of IlorinJohns Hopkins Bloomberg School of Public HealthDepartment of Medicine and Surgery, University of IlorinDepartment of Medicine and Surgery, University of IlorinNewark Beth Israel Medical CenterKornberg School of Dentistry, Temple UniversityDepartment of Medicine, Ladoke Akintola University of TechnologyAbstract Anticoagulation therapy is a critical component of post-transcatheter aortic valve implantation (TAVI) management, aimed at reducing the risk of thromboembolic events and mortality. This review examines the efficacy of continuous versus interrupted anticoagulation strategies in TAVI patients, focusing on mortality, stroke rates, and composite events. A literature review was conducted, analyzing recent studies that evaluate the impact of different anticoagulation regimens on clinical outcomes in TAVI patients. Key outcomes assessed include all-cause mortality, thromboembolic events, and major cardiovascular complications within 30 days and up to one year post-procedure. The review identifies a trend favoring continuous anticoagulation, particularly with direct-acting oral anticoagulants (DOACs), which was associated with lower mortality rates and reduced stroke incidence in high-risk patients. However, findings were inconsistent across studies, with some reporting no significant differences in outcomes between continuous and interrupted strategies. Additionally, the review highlights the need to balance the benefits of thromboembolic prevention with the increased risk of bleeding and vascular complications associated with continuous therapy. The findings show the importance of individualized anticoagulation strategies tailored to patient risk profiles. Clinicians should weigh the potential benefits of continuous anticoagulation against the risks, particularly in high-risk populations. Ongoing research is essential to refine anticoagulation protocols in TAVI patients, enhancing both safety and efficacy in clinical practice.https://doi.org/10.1186/s12959-025-00686-zAnticoagulationTranscatheter Aortic Valve Implantation (TAVI)Direct Oral Anticoagulants (DOACs)Thromboembolic Events |
| spellingShingle | Ravi Patel Emmanuel Kokori Gbolahan Olatunji Israel Charles Abraham Adeola Akinboade Emmanuel Ababio Agyemang Adetola Babalola Nicholas Aderinto Balancing the risks: continuous vs. interrupted anticoagulation during TAVI – what does the evidence say? Thrombosis Journal Anticoagulation Transcatheter Aortic Valve Implantation (TAVI) Direct Oral Anticoagulants (DOACs) Thromboembolic Events |
| title | Balancing the risks: continuous vs. interrupted anticoagulation during TAVI – what does the evidence say? |
| title_full | Balancing the risks: continuous vs. interrupted anticoagulation during TAVI – what does the evidence say? |
| title_fullStr | Balancing the risks: continuous vs. interrupted anticoagulation during TAVI – what does the evidence say? |
| title_full_unstemmed | Balancing the risks: continuous vs. interrupted anticoagulation during TAVI – what does the evidence say? |
| title_short | Balancing the risks: continuous vs. interrupted anticoagulation during TAVI – what does the evidence say? |
| title_sort | balancing the risks continuous vs interrupted anticoagulation during tavi what does the evidence say |
| topic | Anticoagulation Transcatheter Aortic Valve Implantation (TAVI) Direct Oral Anticoagulants (DOACs) Thromboembolic Events |
| url | https://doi.org/10.1186/s12959-025-00686-z |
| work_keys_str_mv | AT ravipatel balancingtheriskscontinuousvsinterruptedanticoagulationduringtaviwhatdoestheevidencesay AT emmanuelkokori balancingtheriskscontinuousvsinterruptedanticoagulationduringtaviwhatdoestheevidencesay AT gbolahanolatunji balancingtheriskscontinuousvsinterruptedanticoagulationduringtaviwhatdoestheevidencesay AT israelcharlesabraham balancingtheriskscontinuousvsinterruptedanticoagulationduringtaviwhatdoestheevidencesay AT adeolaakinboade balancingtheriskscontinuousvsinterruptedanticoagulationduringtaviwhatdoestheevidencesay AT emmanuelababioagyemang balancingtheriskscontinuousvsinterruptedanticoagulationduringtaviwhatdoestheevidencesay AT adetolababalola balancingtheriskscontinuousvsinterruptedanticoagulationduringtaviwhatdoestheevidencesay AT nicholasaderinto balancingtheriskscontinuousvsinterruptedanticoagulationduringtaviwhatdoestheevidencesay |